The next wave of protein therapeutics, based on non-traditional scaffolds, may offer advantages in the range of conditions they can treat, delivery, and manufacturing. But they are just beginning to prove themselves in the clinic.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Hendricus Hoogenboom, chief scientific officer, Ablynx, Ghent, Belgium
Anti-infective antibodies: finding the path forward
Web links
Rights and permissions
About this article
Cite this article
Sheridan, C. Pharma consolidates its grip on post-antibody landscape. Nat Biotechnol 25, 365–366 (2007). https://doi.org/10.1038/nbt0407-365
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0407-365
